Assort Health has closed a $120 million Series C led by Menlo Ventures at a $1.2 billion post-money valuation, according to a June 24 funding roundup. The raise pushes the healthcare-AI company into unicorn status and ranks among the larger applied-AI rounds of the month.
The company builds AI agents for patient access -- the sprawling administrative layer that sits between patients and care. Its systems automate appointment scheduling, intake, referrals, document processing and front-desk staff support, the high-volume, repetitive tasks that consume enormous staff time and drive both cost and patient frustration in provider organizations. Crucially, this is automation embedded in operational workflows, not a standalone chatbot.
The profile fits a clear 2026 pattern: investors are paying premium prices for AI that demonstrates measurable deployment scale, regulatory compliance and embedded workflows rather than generic capability claims. Healthcare administration is an especially attractive target because the labor is expensive, the tasks are structured, and the ROI is quantifiable -- every automated call or referral is a direct cost saving.
“Notably, Menlo Ventures led, the same firm that just closed a record $3 billion fund off its Anthropic bet.”
The competitive landscape is crowded and well-funded. Voice and agent startups like Hippocratic AI, and incumbents from Epic to Commure, are all chasing healthcare's administrative spend, while horizontal agent platforms circle from above. Assort's bet is depth: that a vertical agent tuned to the specific compliance and integration realities of provider operations will out-execute general-purpose copilots. The same logic -- vertical beats horizontal in regulated industries -- is drawing capital across legal, insurance and financial-services AI.
Notably, Menlo Ventures led, the same firm that just closed a record $3 billion fund off its Anthropic bet. Deploying into applied vertical AI like Assort is a signal of where that capital is heading: not just into frontier labs, but into the companies turning model capability into booked enterprise revenue.
What to watch: whether Assort can defend its margins as foundation-model voice capabilities commoditize, how quickly it expands beyond patient access into adjacent revenue-cycle workflows, and whether $1.2B proves conservative or rich as the vertical-agent category matures.